Alexza Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alexza.com
Staccato Loxapine Pulmonary Safety in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Inhaled Placebo
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00889837
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
Staccato Loxapine Pulmonary Safety in Patients With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Inhaled loxapine @ 0 & 10 hDrug: Inhaled placebo @ 2 & 10 hours
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00890175
- Locations
- 🇺🇸
Allergy and Asthma Medical Group & Research Center, A.P.C., San Diego, California, United States
Staccato Loxapine PK in Smokers and Nonsmokers
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00873769
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Evansville, Indiana, United States
Staccato Loxapine Thorough QT/QTc Study
- Conditions
- Thorough QT/QTc Study
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00874237
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
Staccato Loxapine in Migraine (Out Patient)
- Conditions
- Migraine Headache
- Interventions
- Drug: Inhaled Loxapine 1.25 mgDrug: Inhaled Loxapine 2.5 mgDrug: Inhaled Placebo
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT00825500
- Locations
- 🇺🇸
CNS Research, Inc., East Providence, Rhode Island, United States
🇺🇸Roger K. Cady, Springfield, Missouri, United States
🇺🇸Elkind Headache Center, Mount Vernon, New York, United States
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00789360
- Locations
- 🇺🇸
Northeast Medical Research, North Dartmouth, Massachusetts, United States
Staccato Loxapine in Agitated Patients With Bipolar Disorder
- Conditions
- Bipolar I Disorder
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT00721955
- Locations
- 🇺🇸
Collaborative NeuroScience Network, Inc., Garden Grove, California, United States
🇺🇸Synergy Escondido, Escondido, California, United States
🇺🇸FutureSearch Trials, Austin, Texas, United States
Staccato Loxapine in Agitated Patients With Schizophrenia
- Conditions
- Patients With Schizophrenia and Acute Agitation
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT00628589
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
Staccato Zaleplon Single Dose Pharmacokinetics
- Conditions
- Healthy
- Interventions
- Drug: Inhaled Zaleplon 2 mgDrug: Inhaled Zaleplon 4 mgDrug: Inhaled Zaleplon 0.5 mgDrug: Inhaled Zaleplon 1 mgDrug: Inhaled placebo
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00620620
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
Staccato Prochlorperazine Single Dose PK Study
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00610727
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States